Oncology Citius’ Leonard Mazur talks targeted immune therapy for CTCL Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals, discusses the launch of its first FDA-approved drug, Lymphir, for CTCL.
Oncology ESMO25: The changing landscape of rare oncology, with Jan Ki... ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.
Oncology Sponsored Addressing the oncological ‘other’: How predictive analysis ... In a new report, ‘Helping others: unlocking the potential of
Oncology Sponsored Understanding and addressing care disparities in rare cancer... Any cancer diagnosis is scary and signals a long, challenging road ahead.
News Daiichi gets speedy FDA review for rare cancer drug Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT).
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.